Pre-market movers: AI platforms, fitness deals, and antiviral breakthroughs

Hey 360 - here are some of our top movers today!

🧨 Special Invite Only Event, This Wednesday March 5th at 9am. Watch to see if JW can call out another 50% SPY options runner and learn how he’s finding these gems. Please register here.

Be the best prepared trader on the Street!

FOCUS LIST🔎

CYCU - Up over 27% in the pre-market after announcing U.S. launch of its AI driven SaaS ARx platform targeted to the corporate sector

TRNR - Up over 20% in pre after announcing it has secured an exclusive distribution and initial order for CLMBR in the United Kingdom

NNVC - Up over 10% in pre after announcing  NV-387 promises to be an effective drug to treat patients affected by measles outbreak

HOTLIST🔥

CYCU - Up over 27% in the pre-market after announcing U.S. launch of its AI driven SaaS ARx platform targeted to the corporate sector 

Cycurion Inc. (CYCU) provides network communications and information technology security solutions.

In the pre-market this morning, the company announced the availability of its ARx Platform targeted for the corporate sector. 

The ARx Platform has solidified its reputation with key government bodies, including the U.S. Department of Justice (DOJ), the Department of Defense (DOD), and numerous state and local governments, while also gaining traction in the public sector. On February 24, 2025, Cycurion announced a landmark 24-36-month partnership with a national public health association, extending ARx to thousands of healthcare organizations nationwide.

Building on the momentum with government and public sector clients, Cycurion has now launched the ARx Platform into the corporate sector, where, to date, it has been met with an equally warm reception.

Shares of CYCU traded up over 19% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $0.8376. Beyond that, $0.90, $0.9890, $1.30 and $1.61 come into play.

Below $0.8376, targets to the downside are $0.75, $0.6840 and then a gap fill at $0.6011.

TRNR - Up over 20% in pre after announcing it has secured an exclusive distribution and initial order for CLMBR in the United Kingdom

Interactive Strength Inc. (TRNR) doing business as FORME, operates a digital fitness platform that provides connected fitness hardware products and related accessories in the United States.

In the pre-market this morning, the company announced that it has secured exclusive distribution and an initial order for CLMBR in the United Kingdom, the 2nd largest international fitness market and 3rd largest globally including the United States.

The United Kingdom is the world's 3rd largest fitness market

New UK Partner, Cranlea Human Performance, has sold CLMBRs to leading UK health clubs, including David Lloyd Clubs

Cranlea's 50-Year History and Leading In-Market Relationships are expected to significantly strengthen CLMBR's position in the UK

Shares of TRNR traded up over 15% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $3.07. Beyond that, $3.40, $3.96, $4.31 and $5.50 come into play.

Below $3.07, targets to the downside are $2.87, $2.72, $2.50 and then a gap fill at $2.31 come into play.

NNVC - Up over 10% in pre after announcing  NV-387 promises to be an effective drug to treat patients affected by measles outbreak

NanoViricides Inc. (NNVC) is a clinical stage nano-biopharmaceutical company that discovers, develops, and commercializes drugs for the treatment of viral infections.

In the pre-market this morning, the company announced that it believes that NV-387, the Company's flagship broad-spectrum antiviral, would be a potentially effective treatment for measles, and is worth evaluating during the current emergency situation created by the spreading outbreak. 

NV-387 is a broad-spectrum antiviral drug that has been found to be effective against many distinctly different virus families that use heparan sulfate proteoglycans (HSPG) during attachment to infect cells, including RSV, Influenza, COVID/Coronaviruses and Mpox/Smallpox[2].

The company believes that  it is highly likely that NV-387 should work against measles based on studies that clearly indicate measles virus also uses HSPG during attachment to infect cells[3].

Shares of NNVC traded up over 10% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $1.41. Beyond that, $1.50, $1.55, $1.65, $1.70, $1.80 and $2 come into play.

Below $1.41, targets to the downside are $1.24 and then a gap fill at $1.19, with $1.04 below that.

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed 🚀past the MOON 🌝.  Text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “Alerts” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.